Cantor Fitzgerald set a $10.00 target price on Bellicum Pharmaceuticals (NASDAQ:BLCM) in a report released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on BLCM. Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 12th. SunTrust Banks dropped their price target on shares of Bellicum Pharmaceuticals to $18.00 and set a buy rating on the stock in a research report on Wednesday, January 31st. Raymond James Financial reissued a buy rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine raised shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, January 3rd. Finally, BidaskClub lowered shares of Bellicum Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $16.88.

How to Become a New Pot Stock Millionaire

Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $8.08 on Tuesday. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 12-month low of $5.02 and a 12-month high of $15.55. The firm has a market cap of $267.04, a PE ratio of -2.70 and a beta of 0.44.

In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of Bellicum Pharmaceuticals stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total value of $2,248,978.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders sold 1,141,822 shares of company stock worth $9,475,583. Insiders own 18.77% of the company’s stock.

A number of hedge funds have recently made changes to their positions in BLCM. Nationwide Fund Advisors raised its position in Bellicum Pharmaceuticals by 30.4% in the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,620 shares during the period. New York State Common Retirement Fund raised its position in shares of Bellicum Pharmaceuticals by 30.8% in the second quarter. New York State Common Retirement Fund now owns 28,000 shares of the biopharmaceutical company’s stock valued at $327,000 after purchasing an additional 6,599 shares during the period. Northern Trust Corp raised its position in shares of Bellicum Pharmaceuticals by 29.5% in the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after purchasing an additional 77,760 shares during the period. Vanguard Group Inc. raised its position in shares of Bellicum Pharmaceuticals by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after purchasing an additional 144,854 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Bellicum Pharmaceuticals in the second quarter valued at approximately $474,000. 55.14% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/bellicum-pharmaceuticals-blcm-given-a-10-00-price-target-at-cantor-fitzgerald.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.